A framework for highly multiplexed dextramer mapping
- Lieven
- 0
A framework for extremely multiplexed dextramer mapping and prediction of T cell receptor sequences to antigen specificity
T cell receptor (TCR) antigen-specific recognition is important for the adaptive immune system. Nonetheless, constructing a TCR-antigen interplay map has been difficult because of the staggering range of TCRs and antigens. Accordingly, extremely multiplexed dextramer-TCR binding assays have been lately developed, however the utility of the following giant datasets is proscribed by the dearth of strong computational strategies for normalization and interpretation.
Right here, we current a computational framework comprising a novel technique, ICON (Integrative COntext-specific Normalization), for figuring out dependable TCR-pMHC (peptide-major histocompatibility complicated) interactions and a neural network-based classifier TCRAI that outperforms different state-of-the-art strategies for TCR-antigen specificity prediction. We additional demonstrated that by combining ICON and TCRAI, we’re in a position to uncover novel subgroups of TCRs that bind to a given pMHC through completely different mechanisms. Our framework facilitates the identification and understanding of TCR-antigen-specific interactions for fundamental immunological analysis and scientific immune monitoring.
EBAG9 (NM_004215) Human Recombinant Protein |
|||
PROTO00559 | BosterBio | 20ug | EUR 1249 |
Description: Recombinant protein of human estrogen receptor binding site associated, antigen, 9 (EBAG9), transcript variant 1 |
EBAG9 Protein, Human, Recombinant (His Tag) |
|||
MBS8121611-01mg | MyBiosource | 0.1mg | EUR 450 |
EBAG9 Protein, Human, Recombinant (His Tag) |
|||
MBS8121611-5x01mg | MyBiosource | 5x0.1mg | EUR 1885 |
OPCA03845-1MG - EBAG9 Recombinant Protein (Human) |
|||
OPCA03845-1MG | Aviva Systems Biology | 1mg | EUR 1379 |
OPCA03845-20UG - EBAG9 Recombinant Protein (Human) |
|||
OPCA03845-20UG | Aviva Systems Biology | 20ug | EUR 218 |
OPCA03845-100UG - EBAG9 Recombinant Protein (Human) |
|||
OPCA03845-100UG | Aviva Systems Biology | 100ug | EUR 323 |
Recombinant Human RCAS1 / EBAG9 protein (His tag) |
|||
PDEH100304-100ug | Elabscience Biotech | 100ug | EUR 118 |
Description: Human |
Recombinant Human RCAS1 / EBAG9 protein (His tag) |
|||
PDEH100304-20ug | Elabscience Biotech | 20ug | EUR 68 |
Description: Human |
Recombinant Human RCAS1/EBAG9 protein (His tag) |
|||
MBS2570902-002mg | MyBiosource | 0.02mg | EUR 135 |
Recombinant Human RCAS1/EBAG9 protein (His tag) |
|||
MBS2570902-01mg | MyBiosource | 0.1mg | EUR 170 |
Recombinant Human RCAS1/EBAG9 protein (His tag) |
|||
MBS2570902-5x01mg | MyBiosource | 5x0.1mg | EUR 765 |
Recombinant Rat EBAG9 Protein, His (Fc)-Avi-tagged |
|||
EBAG9-1654R | Creative BioMart | 50ug | EUR 2398.4 |
Description: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles. |
Recombinant Mouse EBAG9 Protein, His (Fc)-Avi-tagged |
|||
EBAG9-2613M | Creative BioMart | 50ug | EUR 2398.4 |
Description: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles. |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-1mg |
|||
QP5959-ec-1mg | EnQuireBio | 1mg | EUR 1958.4 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-10ug |
|||
QP5959-ec-10ug | EnQuireBio | 10ug | EUR 240 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-50ug |
|||
QP5959-ec-50ug | EnQuireBio | 50ug | EUR 315.6 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-100ug |
|||
QP5959-ec-100ug | EnQuireBio | 100ug | EUR 489.6 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-200ug |
|||
QP5959-ec-200ug | EnQuireBio | 200ug | EUR 760.8 |
Recombinant Human RCAS1/ EBAG9 Protein, His-SUMO, E.coli-500ug |
|||
QP5959-ec-500ug | EnQuireBio | 500ug | EUR 1272 |
EBAG9 protein (His tag) |
|||
80R-1093 | Fitzgerald | 100 ug | EUR 219 |
Description: Purified recombinant Human EBAG9 protein |
Human EBAG9 Protein Lysate |
|||
MBS8410846-002mg | MyBiosource | 0.02mg | EUR 365 |
Human EBAG9 Protein Lysate |
|||
MBS8410846-5x002mg | MyBiosource | 5x0.02mg | EUR 1410 |
OPPA02054-10UG - EBAG9 Protein |
|||
OPPA02054-10UG | Aviva Systems Biology | 10ug | EUR 70 |
Human EBAG9 Protein, His Tag |
|||
E40KMPH4470 | EnoGene | 20ug | EUR 495 |
Human EBAG9 Protein Lysate 20ug |
|||
IHUEBAG9PLLY20UG | Innovative research | each | EUR 213 |
Description: Human EBAG9 Protein Lysate 20ug |
OCOA20218-20UG - EBAG9 Protein Lysate |
|||
OCOA20218-20UG | Aviva Systems Biology | 20ug | EUR 169 |
OCOA13214-20UG - EBAG9 Protein Lysate |
|||
OCOA13214-20UG | Aviva Systems Biology | 20ug | EUR 169 |
OCOA04155-20UG - EBAG9 Protein Lysate |
|||
OCOA04155-20UG | Aviva Systems Biology | 20ug | EUR 169 |
EBAG9 Protein Vector (Rat) (pPM-C-HA) |
|||
PV265296 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Rat) (pPB-C-His) |
|||
PV265294 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Rat) (pPB-N-His) |
|||
PV265295 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Rat) (pPM-C-His) |
|||
PV265297 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Human) (pPM-C-HA) |
|||
PV013463 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPM-C-HA) |
|||
PV013467 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV174240 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Human) (pPB-C-His) |
|||
PV013461 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPB-N-His) |
|||
PV013462 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPM-C-His) |
|||
PV013464 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPB-C-His) |
|||
PV013465 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPB-N-His) |
|||
PV013466 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Human) (pPM-C-His) |
|||
PV013468 | ABM | 500 ng | EUR 394.8 |
EBAG9 Protein Vector (Mouse) (pPB-C-His) |
|||
PV174238 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Mouse) (pPB-N-His) |
|||
PV174239 | ABM | 500 ng | EUR 723.6 |
EBAG9 Protein Vector (Mouse) (pPM-C-His) |
|||
PV174241 | ABM | 500 ng | EUR 723.6 |
EBAG9 |
|||
CSB-CL007355HU1 | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
EBAG9 |
|||
CSB-CL007355HU2 | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
EBAG9 |
|||
pro-343 | ProSpec Tany | 10µg | EUR 60 |
Description: Recombinant Human Estrogen Receptor Binding Site Associated Antigen 9 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-005mgBaculovirus | MyBiosource | 0.05mg(Baculovirus) | EUR 1115 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-005mgMammalianCell | MyBiosource | 0.05mg(Mammalian-Cell) | EUR 1335 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-05mgEColi | MyBiosource | 0.5mg(E-Coli) | EUR 1115 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-05mgYeast | MyBiosource | 0.5mg(Yeast) | EUR 1335 |
Recombinant Dog Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
MBS1349708-1mgEColi | MyBiosource | 1mg(E-Coli) | EUR 1635 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-005mgBaculovirus | MyBiosource | 0.05mg(Baculovirus) | EUR 1115 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-005mgMammalianCell | MyBiosource | 0.05mg(Mammalian-Cell) | EUR 1335 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-05mgEColi | MyBiosource | 0.5mg(E-Coli) | EUR 1115 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-05mgYeast | MyBiosource | 0.5mg(Yeast) | EUR 1335 |
Recombinant Rat Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1430359-1mgEColi | MyBiosource | 1mg(E-Coli) | EUR 1635 |
Recombinant Human Receptor-binding cancer antigen expressed on SiSo cells(EBAG9),partial |
|||
AP70252 | SAB | 1mg | EUR 1978 |
Recombinant Human Receptor-binding cancer antigen expressed on SiSo cells (EBAG9), partial |
|||
CSB-EP007355HU | Cusabio | 1056 mg | Ask for price |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-005mgBaculovirus | MyBiosource | 0.05mg(Baculovirus) | EUR 1115 |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-005mgMammalianCell | MyBiosource | 0.05mg(Mammalian-Cell) | EUR 1335 |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-05mgEColi | MyBiosource | 0.5mg(E-Coli) | EUR 1115 |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-05mgYeast | MyBiosource | 0.5mg(Yeast) | EUR 1335 |
Recombinant Mouse Receptor-binding cancer antigen expressed on SiSo cells (Ebag9), partial |
|||
MBS1320693-1mgEColi | MyBiosource | 1mg(E-Coli) | EUR 1635 |
Monoclonal EBAG9 Antibody (monoclonal) (M04), Clone: 4A10 |
|||
AMM03477G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human EBAG9 (monoclonal) (M04). The antibodies are raised in mouse and are from clone 4A10. This antibody is applicable in WB, E |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-002mgWithBSAAzideat02mgmL | MyBiosource | 0.02mg(WithBSA&Azideat0.2mg/mL) | EUR 230 |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-01mgWithBSAAzideat02mgmL | MyBiosource | 0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 405 |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-01mgWithoutBSAAzideat1mgmL | MyBiosource | 0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 405 |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-5x01mgWithBSAAzideat02mgmL | MyBiosource | 5x0.1mg(WithBSA&Azideat0.2mg/mL) | EUR 1725 |
RCAS1/Estrogen Receptor Binding Site Associated, Antigen 9 Recombinant Rabbit Monoclonal Antibody [Clone EBAG9/7033R] |
|||
MBS4382356-5x01mgWithoutBSAAzideat1mgmL | MyBiosource | 5x0.1mg(WithoutBSA&Azideat1mg/mL) | EUR 1725 |
EBAG9 siRNA |
|||
20-abx914879 | Abbexa |
|
|
EBAG9 siRNA |
|||
20-abx914880 | Abbexa |
|
|
EBAG9 siRNA |
|||
20-abx901624 | Abbexa |
|
|
EBAG9 Peptide |
|||
45-515P | ProSci | 0.1 mg | EUR 405.6 |
Description: EBAG9 / RCAS1 Peptide |
EBAG9 antibody |
|||
38323 | SAB | 100ul | EUR 439 |
EBAG9 antibody |
|||
38323-100ul | SAB | 100ul | EUR 302.4 |
EBAG9 Antibody |
|||
DF6703 | Affbiotech | 200ul | EUR 420 |
EBAG9 Antibody |
|||
DF6703-100ul | Affinity Biosciences | 100ul | EUR 280 |
EBAG9 Antibody |
|||
DF6703-200ul | Affinity Biosciences | 200ul | EUR 350 |
EBAG9 Antibody |
|||
E91935 | EnoGene | 100μg | EUR 255 |
Description: Available in various conjugation types. |
EBAG9 Antibody |
|||
E300798 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
EBAG9 Antibody |
|||
E300799 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
EBAG9 antibody |
|||
70R-16981 | Fitzgerald | 50 ul | EUR 289 |
Description: Rabbit polyclonal EBAG9 antibody |
EBAG9 antibody |
|||
70R-9916 | Fitzgerald | 50 ug | EUR 467 |
Description: Affinity purified rabbit polyclonal EBAG9 antibody |
EBAG9 Antibody |
|||
1-CSB-PA007355GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against EBAG9. Recognizes EBAG9 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
EBAG9 Antibody |
|||
ABD6703 | Nova Lifetech | 100ug | EUR 325 |
EBAG9 Antibody |
|||
GWB-MV765I | GenWay Biotech | 50ug | Ask for price |
EBAG9 Antibody |
|||
R34393-100UG | NSJ Bioreagents | 100 ug | EUR 339.15 |
Description: Additional name(s) for this target protein: Estrogen receptor binding site associated, antigen, 9, RCAS1 |
EBAG9 Antibody |
|||
R31790 | NSJ Bioreagents | 100 ug | EUR 356.15 |
Description: Receptor-binding cancer antigen expressed on SiSo cells is a protein that in humans is encoded by the EBAG9 gene. This gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor, which binds to the estrogen-responsive element found in the 5'-flanking region of this gene. And the encoded protein is a tumor-associated antigen that is expressed at high frequency in a variety of cancers. Alternate splicing results in multiple transcript variants. A pseudogene of this gene has been defined on chromosome 10. |
EBAG9 Antibody |
|||
K40051M04H07C-100ug | Absea Biotechnology | 100 ug | EUR 360 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M04H07C-1mg | Absea Biotechnology | 1 mg | EUR 1800 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M04H07C-50ug | Absea Biotechnology | 50 ug | EUR 252 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M10A09C-100ug | Absea Biotechnology | 100 ug | EUR 320 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M10A09C-1mg | Absea Biotechnology | 1 mg | EUR 1600 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M10A09C-50ug | Absea Biotechnology | 50 ug | EUR 224 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M14G10C-100ug | Absea Biotechnology | 100 ug | EUR 280 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M14G10C-1mg | Absea Biotechnology | 1 mg | EUR 1400 |
Description: Monoclonal Antibody |
EBAG9 Antibody |
|||
K40051M14G10C-50ug | Absea Biotechnology | 50 ug | EUR 196 |
Description: Monoclonal Antibody |
EBAG9 antibody |
|||
MBS9405267-005mL | MyBiosource | 0.05mL | EUR 300 |
EBAG9 antibody |
|||
MBS9405267-01mL | MyBiosource | 0.1mL | EUR 390 |
EBAG9 antibody |
|||
MBS9405267-5x01mL | MyBiosource | 5x0.1mL | EUR 1610 |
EBAG9 Antibody |
|||
MBS854957-01mg | MyBiosource | 0.1mg | EUR 345 |
EBAG9 Antibody |
|||
MBS854957-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
EBAG9 Antibody |
|||
MBS854957-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
EBAG9 Antibody |
|||
MBS854957-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
EBAG9 Antibody |
|||
MBS854957-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
EBAG9 Antibody |
|||
MBS854258-01mg | MyBiosource | 0.1mg | EUR 345 |
EBAG9 Antibody |
|||
MBS854258-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
EBAG9 Antibody |
|||
MBS854258-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
EBAG9 Antibody |
|||
MBS854258-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
EBAG9 Antibody |
|||
MBS854258-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
EBAG9 Antibody |
|||
MBS8505315-01mg | MyBiosource | 0.1mg | EUR 325 |
EBAG9 Antibody |
|||
MBS8505315-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
EBAG9 Antibody |
|||
MBS8505315-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
EBAG9 Antibody |
|||
MBS8505315-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
EBAG9 Antibody |
|||
MBS8505315-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
EBAG9 Antibody |
|||
MBS2523105-006mL | MyBiosource | 0.06mL | EUR 190 |
EBAG9 Antibody |
|||
MBS2523105-012mL | MyBiosource | 0.12mL | EUR 265 |
EBAG9 Antibody |
|||
MBS2523105-02mL | MyBiosource | 0.2mL | EUR 415 |
EBAG9 Antibody |
|||
MBS2523105-5x02mL | MyBiosource | 5x0.2mL | EUR 1835 |
EBAG9 Antibody |
|||
MBS9607359-01mL | MyBiosource | 0.1mL | EUR 260 |
EBAG9 Antibody |
|||
MBS9607359-02mL | MyBiosource | 0.2mL | EUR 305 |
EBAG9 Antibody |
|||
MBS9607359-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
Active Recombinant Human ICAM1 Protein (28-480aa), C-hIgG-His-tagged |
|||
ICAM1-14H | Creative BioMart | 5ug | EUR 158.4 |
Description: Can be stored at +2 to +8 centigrade for 1 week. For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles. |
EBAG9 siRNA (Rat) |
|||
MBS8206041-15nmol | MyBiosource | 15nmol | EUR 405 |
EBAG9 siRNA (Rat) |
|||
MBS8206041-30nmol | MyBiosource | 30nmol | EUR 565 |
EBAG9 siRNA (Rat) |
|||
MBS8206041-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
EBAG9 Rabbit pAb |
|||
A8385-200ul | Abclonal | 200 ul | EUR 550.8 |
EBAG9 Rabbit pAb |
|||
A8385-20ul | Abclonal | 20 ul | Ask for price |
EBAG9 Rabbit pAb |
|||
E2501935 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
EBAG9 Rabbit pAb |
|||
A1935-100ul | Abclonal | 100 ul | EUR 369.6 |
EBAG9 Rabbit pAb |
|||
A1935-200ul | Abclonal | 200 ul | EUR 550.8 |
EBAG9 Rabbit pAb |
|||
A1935-20ul | Abclonal | 20 ul | EUR 219.6 |
EBAG9 Rabbit pAb |
|||
A1935-50ul | Abclonal | 50 ul | EUR 267.6 |
EBAG9 cDNA Clone |
|||
MBS1269322-001mgPlasmid02mLGlycerolStock | MyBiosource | 0.01mgPlasmid+0.2mLGlycerol-Stock | EUR 200 |
EBAG9 cDNA Clone |
|||
MBS1269322-5x001mgPlasmid5x02mLGlycerolStock | MyBiosource | 5x0.01mgPlasmid+5x0.2mLGlycerol-Stock | EUR 855 |
EBAG9 cDNA Clone |
|||
MBS1273084-001mgPlasmid02mLGlycerolStock | MyBiosource | 0.01mgPlasmid+0.2mLGlycerol-Stock | EUR 200 |
EBAG9 cDNA Clone |
|||
MBS1273084-5x001mgPlasmid5x02mLGlycerolStock | MyBiosource | 5x0.01mgPlasmid+5x0.2mLGlycerol-Stock | EUR 855 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mL | MyBiosource | 0.1mL | EUR 305 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
EBAG9 Rabbit pAb |
|||
MBS8544680-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
EBAG9 Rabbit pAb |
|||
A1935 | Abclonal | 50μL | EUR 173.58 |
EBAG9 Rabbit pAb |
|||
A8385 | Abclonal | 200μL | EUR 173.58 |
EBAG9 siRNA (Mouse) |
|||
MBS8232252-15nmol | MyBiosource | 15nmol | EUR 405 |
EBAG9 siRNA (Mouse) |
|||
MBS8232252-30nmol | MyBiosource | 30nmol | EUR 565 |
EBAG9 siRNA (Mouse) |
|||
MBS8232252-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
EBAG9 siRNA (Human) |
|||
MBS8241103-15nmol | MyBiosource | 15nmol | EUR 405 |
EBAG9 siRNA (Human) |
|||
MBS8241103-30nmol | MyBiosource | 30nmol | EUR 565 |
EBAG9 siRNA (Human) |
|||
MBS8241103-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
Human EBAG9 Antibody |
|||
32605-05111 | AssayPro | 150 ug | EUR 215 |
EBAG9 Antibody / RCAS1 |
|||
V5262-100UG | NSJ Bioreagents | 100ug | EUR 363.3 |
Description: EBAG9 (Estrogen receptor-binding fragment-associated gene 9 protein), also known as RCAS1, is an estrogen-transcribed protein. Soluble and membranous RCAS1 proteins may play a role in the immune escape of tumor cells by promoting T lymphocyte inhibition of growth and apoptosis. RCAS1 is expressed in a wide variety of cancers, including uterine, ovarian, and lung cancer cells, and acts as a ligand for a putative receptor present on peripheral lymphocytes. RCAS1 is highly expressed not only in cancer cells but also in non-tumor bile duct cells subject to immune attack. RCAS1 inhibits the in vitro growth of receptor-expressing cells and induces apoptosis, contributing to the ability of tumor cells to evade host immune surveillance. High expression of RCAS1 significantly correlates with tumor progression and with poor outcome for many cancer patients. |
EBAG9 Antibody / RCAS1 |
|||
V5262-20UG | NSJ Bioreagents | 20ug | EUR 160.3 |
Description: EBAG9 (Estrogen receptor-binding fragment-associated gene 9 protein), also known as RCAS1, is an estrogen-transcribed protein. Soluble and membranous RCAS1 proteins may play a role in the immune escape of tumor cells by promoting T lymphocyte inhibition of growth and apoptosis. RCAS1 is expressed in a wide variety of cancers, including uterine, ovarian, and lung cancer cells, and acts as a ligand for a putative receptor present on peripheral lymphocytes. RCAS1 is highly expressed not only in cancer cells but also in non-tumor bile duct cells subject to immune attack. RCAS1 inhibits the in vitro growth of receptor-expressing cells and induces apoptosis, contributing to the ability of tumor cells to evade host immune surveillance. High expression of RCAS1 significantly correlates with tumor progression and with poor outcome for many cancer patients. |
EBAG9 Antibody / RCAS1 |
|||
V5262SAF-100UG | NSJ Bioreagents | 100ug | EUR 363.3 |
Description: EBAG9 (Estrogen receptor-binding fragment-associated gene 9 protein), also known as RCAS1, is an estrogen-transcribed protein. Soluble and membranous RCAS1 proteins may play a role in the immune escape of tumor cells by promoting T lymphocyte inhibition of growth and apoptosis. RCAS1 is expressed in a wide variety of cancers, including uterine, ovarian, and lung cancer cells, and acts as a ligand for a putative receptor present on peripheral lymphocytes. RCAS1 is highly expressed not only in cancer cells but also in non-tumor bile duct cells subject to immune attack. RCAS1 inhibits the in vitro growth of receptor-expressing cells and induces apoptosis, contributing to the ability of tumor cells to evade host immune surveillance. High expression of RCAS1 significantly correlates with tumor progression and with poor outcome for many cancer patients. |
EBAG9 cloning plasmid |
|||
CSB-CL007355HU1-10ug | Cusabio | 10ug | EUR 279.6 |
Description: A cloning plasmid for the EBAG9 gene. |
EBAG9 cloning plasmid |
|||
CSB-CL007355HU2-10ug | Cusabio | 10ug | EUR 279.6 |
Description: A cloning plasmid for the EBAG9 gene. |
EBAG9 Antibody (Center) |
|||
MBS9232087-01mL | MyBiosource | 0.1mL | EUR 435 |
EBAG9 Antibody (Center) |
|||
MBS9232087-5x01mL | MyBiosource | 5x0.1mL | EUR 1625 |
EBAG9 Antibody (Center) |
|||
MBS9202634-008mL | MyBiosource | 0.08mL | EUR 210 |
Quantifying persistence within the T-cell signaling community utilizing an optically controllable antigen receptor
T cells discriminate between wholesome and contaminated cells with outstanding sensitivity when mounting an immune response, which is hypothesized to rely upon T cells combining stimuli from a number of antigen-presenting cell interactions right into a stronger response. To quantify the capability for T cells to perform this, now we have developed an antigen receptor that’s optically tunable inside cell conjugates, offering management over the period, and depth of intracellular T-cell signaling.
We observe restricted persistence throughout the T-cell intracellular community on disruption of receptor enter, with alerts dissipating completely in ~15 min, and straight present sustained proximal receptor signaling is required to keep up gene transcription. T cells thus primarily accumulate the outputs of gene expression slightly than combine discrete intracellular alerts. Engineering optical management in a clinically related chimeric antigen receptor (CAR), we present that this restricted sign persistence might be exploited to extend CAR-T cell activation threefold utilizing pulsatile stimulation. Our outcomes are prone to apply extra typically to the signaling dynamics of different mobile networks.
Tumor rejection properties of gp100 209-specific T cells correlate with T cell receptor binding affinity in the direction of the wild kind slightly than anchor-modified antigen
Though there are exceptions and outliers, T cell practical responses typically correlate with the affinity of a TCR for a peptide/MHC complicated. In a single lately described outlier case, probably the most promising scientific candidate in a collection of TCRs particular for the gp100209 melanoma antigen sure with the weakest answer affinity and produced the least quantity of cytokine in vitro. Hypotheses for this outlier habits included uncommon cytokine expression patterns arising from an atypical TCR binding geometry. Finding out this occasion in additional element, we discovered right here that outlier habits is attributable to not uncommon cytokine patterns or TCR binding, however using a place 2 anchor-modified peptide variant in in vitro experiments as a substitute of the wild kind antigen that’s current in vivo.
Though the anchor-modified variant has been extensively utilized in fundamental and scientific immunology as a surrogate for the wild kind peptide, prior work has proven that TCRs can clearly distinguish between the 2. We present that when this differential recognition is accounted for, the practical properties of gp100209-specific TCRs monitor with their affinity in the direction of the peptide/MHC complicated. Past demonstrating the correlates with T cell operate for a clinically related TCR, our outcomes present vital concerns for collection of TCRs for immunotherapy and using modified peptides in immunology.
Proliferating cell nuclear antigen straight interacts with androgen receptor and enhances androgen receptor‑mediated signaling
Androgen receptor (AR) and/or its constitutively lively splicing variants (AR‑Vs), resembling AR‑V7 and ARv567es, is required for prostate most cancers cell development and survival, and most cancers development. Proliferating cell nuclear antigen (PCNA) is preferentially overexpressed in all cancers and executes its features by interplay with quite a few accomplice proteins. The intention of the current research was to analyze the potential position of PCNA within the regulation of AR exercise.
An an identical consensus sequence of the PCNA‑interacting protein‑field (PIP‑field) was recognized on the N‑terminus of human, mouse and rat AR proteins. It was discovered that PCNA complexes with the total‑size AR (AR‑FL) and AR‑V7, which might be attenuated by the small molecule PIP‑field inhibitor, T2AA. PCNA additionally complexes with ARv567es and recombinant AR protein. The PCNA inhibitors, PCNA‑I1S and T2AA, inhibited AR transcriptional exercise and the expression of AR goal genes in LNCaP‑AI and 22Rv1 cells, however not in AR‑unfavorable PC‑three cells. The knockdown of PCNA expression lowered dihydrotestosterone‑stimulated AR transcriptional exercise and abolished the inhibitory impact of PCNA‑I1S on AR exercise. The PCNA inhibitor, PCNA‑I1, exerted additive development inhibitory results with androgen deprivation and enzalutamide in cells expressing AR‑FL or AR‑FL/AR‑V7, however not in AR‑unfavorable PC‑three cells.
Lastly, R9‑AR‑PIP, a small peptide mimicking AR PIP‑field, was discovered to bind to GFP‑PCNA at Okayd of two.73 µM and inhibit the expression of AR goal genes, AR transcriptional exercise and the expansion of AR‑expressing cells. On the entire, these information strongly counsel that AR is a PCNA accomplice protein and interacts with PCNA through the PIP‑field and that concentrating on the PCNA‑AR interplay could signify an revolutionary and selective therapeutic technique towards prostate most cancers, significantly castration‑resistant prostate cancers overexpressing constitutively lively AR‑Vs.
Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells successfully remove human glioblastoma
Aims: The growing success of Chimeric Antigen Receptor (CAR) T cell remedy in haematological malignancies is reinvigorating its utility in lots of different most cancers sorts and with renewed deal with its utility to stable tumors. We current a novel CAR towards glioblastoma, an aggressive, malignant glioma, with a dismal survival charge for which remedy choices have remained unchanged for over a decade.
Strategies: We use the human Retained Show (ReD) antibody platform (Myrio Therapeutics) to determine a novel single-chain variable fragment (scFv) that recognises epidermal development issue receptor mutant variant III (EGFRvIII), a typical and tumor-specific mutation present in glioblastoma. We use each in vitro practical assays and an in vivo orthotopic xenograft mannequin of glioblastoma to look at the operate of our novel CAR, known as GCT02, focused utilizing murine CAR T cells.
Outcomes: Our EGFRvIII-specific scFv was discovered to be of a lot increased affinity than reported comparators reverse-engineered from monoclonal antibodies. Regardless of the upper affinity, GCT02 CAR T cells kill equivalently however secrete decrease quantities of cytokine. As well as, GCT02-CAR T cells additionally mediate fast and full tumor elimination in vivo.
Conclusion: We current a novel EGFRvIII-specific CAR, with efficient antitumor features each in in vitro and in a xenograft mannequin of human glioblastoma.
XS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV756093 | ABM | 1.0 ug DNA | Ask for price |
NP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV814303 | ABM | 1.0 ug DNA | EUR 540 |
DM1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV723183 | ABM | 1.0 ug DNA | Ask for price |
DWS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV723519 | ABM | 1.0 ug DNA | Ask for price |
EBM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV723687 | ABM | 1.0 ug DNA | Ask for price |
EGI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV723933 | ABM | 1.0 ug DNA | Ask for price |
F7R Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV724761 | ABM | 1.0 ug DNA | Ask for price |
FND Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV725475 | ABM | 1.0 ug DNA | Ask for price |
UBB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV716533 | ABM | 1.0 ug DNA | EUR 379.2 |
WAC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV716731 | ABM | 1.0 ug DNA | EUR 379.2 |
AFA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV718317 | ABM | 1.0 ug DNA | Ask for price |
AIC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV718395 | ABM | 1.0 ug DNA | Ask for price |
AOM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV718869 | ABM | 1.0 ug DNA | Ask for price |
ATD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV719175 | ABM | 1.0 ug DNA | Ask for price |
GRN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV710665 | ABM | 1.0 ug DNA | EUR 379.2 |
HGF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV710833 | ABM | 1.0 ug DNA | EUR 379.2 |
HGF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV710839 | ABM | 1.0 ug DNA | EUR 379.2 |
HYI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV711145 | ABM | 1.0 ug DNA | EUR 379.2 |
JTB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV711559 | ABM | 1.0 ug DNA | EUR 379.2 |
LBH Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV711901 | ABM | 1.0 ug DNA | EUR 379.2 |
LTF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712075 | ABM | 1.0 ug DNA | EUR 379.2 |
LUM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712087 | ABM | 1.0 ug DNA | EUR 379.2 |
LXN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712093 | ABM | 1.0 ug DNA | EUR 379.2 |
MAX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712171 | ABM | 1.0 ug DNA | EUR 379.2 |
MAX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712177 | ABM | 1.0 ug DNA | EUR 379.2 |
MAX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712183 | ABM | 1.0 ug DNA | EUR 379.2 |
MAX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712189 | ABM | 1.0 ug DNA | EUR 379.2 |
MPI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712369 | ABM | 1.0 ug DNA | EUR 379.2 |
NF2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712735 | ABM | 1.0 ug DNA | EUR 379.2 |
NMI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712777 | ABM | 1.0 ug DNA | EUR 379.2 |
OAT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV712987 | ABM | 1.0 ug DNA | EUR 379.2 |
OS9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV713023 | ABM | 1.0 ug DNA | EUR 379.2 |
JBS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730197 | ABM | 1.0 ug DNA | Ask for price |
JPD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730203 | ABM | 1.0 ug DNA | Ask for price |
KFM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730353 | ABM | 1.0 ug DNA | Ask for price |
KMS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730473 | ABM | 1.0 ug DNA | Ask for price |
KSS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730749 | ABM | 1.0 ug DNA | Ask for price |
KWE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730755 | ABM | 1.0 ug DNA | Ask for price |
LCO Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV730887 | ABM | 1.0 ug DNA | Ask for price |
GTS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV727149 | ABM | 1.0 ug DNA | Ask for price |
HMI Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV728379 | ABM | 1.0 ug DNA | Ask for price |
HPT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV728727 | ABM | 1.0 ug DNA | Ask for price |
HTL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV728973 | ABM | 1.0 ug DNA | Ask for price |
CHR Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV721173 | ABM | 1.0 ug DNA | Ask for price |
CMM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV721407 | ABM | 1.0 ug DNA | Ask for price |
CNC Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV721455 | ABM | 1.0 ug DNA | Ask for price |
COP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV721599 | ABM | 1.0 ug DNA | Ask for price |
CRG Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV721785 | ABM | 1.0 ug DNA | Ask for price |
CRS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV721797 | ABM | 1.0 ug DNA | Ask for price |
CSE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV721839 | ABM | 1.0 ug DNA | Ask for price |
CTD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV721923 | ABM | 1.0 ug DNA | Ask for price |
DCE Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV722337 | ABM | 1.0 ug DNA | Ask for price |
DDU Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV722361 | ABM | 1.0 ug DNA | Ask for price |
RGR Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV714307 | ABM | 1.0 ug DNA | EUR 379.2 |
Sp2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV715321 | ABM | 1.0 ug DNA | EUR 379.2 |
Sp2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV715327 | ABM | 1.0 ug DNA | EUR 379.2 |
Syk Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV715609 | ABM | 1.0 ug DNA | EUR 379.2 |
TK1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV715879 | ABM | 1.0 ug DNA | EUR 379.2 |
TTK Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV716389 | ABM | 1.0 ug DNA | EUR 379.2 |
GCY Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV726561 | ABM | 1.0 ug DNA | Ask for price |
PIP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV713473 | ABM | 1.0 ug DNA | EUR 379.2 |
PTS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV713989 | ABM | 1.0 ug DNA | EUR 379.2 |
CCT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV720669 | ABM | 1.0 ug DNA | Ask for price |
CCV Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV720723 | ABM | 1.0 ug DNA | Ask for price |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV703483 | ABM | 1.0 ug DNA | EUR 540 |
NPL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV703699 | ABM | 1.0 ug DNA | EUR 540 |
FGA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV704107 | ABM | 1.0 ug DNA | EUR 540 |
NNT Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV704257 | ABM | 1.0 ug DNA | EUR 540 |
MSD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV734289 | ABM | 1.0 ug DNA | Ask for price |
NSX Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV736497 | ABM | 1.0 ug DNA | Ask for price |
NT3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV736503 | ABM | 1.0 ug DNA | Ask for price |
OAP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV736659 | ABM | 1.0 ug DNA | Ask for price |
OED Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV736707 | ABM | 1.0 ug DNA | Ask for price |
PIH Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV740319 | ABM | 1.0 ug DNA | Ask for price |
PRD Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV741573 | ABM | 1.0 ug DNA | Ask for price |
PRS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV741753 | ABM | 1.0 ug DNA | Ask for price |
SDU Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV748131 | ABM | 1.0 ug DNA | Ask for price |
SEA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV748137 | ABM | 1.0 ug DNA | Ask for price |
ST2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV749655 | ABM | 1.0 ug DNA | EUR 686.4 |
ST3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV749661 | ABM | 1.0 ug DNA | Ask for price |
ST4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV749673 | ABM | 1.0 ug DNA | Ask for price |
ST8 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV749691 | ABM | 1.0 ug DNA | Ask for price |
RP6 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV747189 | ABM | 1.0 ug DNA | Ask for price |
RSS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV747633 | ABM | 1.0 ug DNA | Ask for price |
S11 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV747687 | ABM | 1.0 ug DNA | Ask for price |
S12 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV747693 | ABM | 1.0 ug DNA | Ask for price |
PDR Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV739875 | ABM | 1.0 ug DNA | Ask for price |
MAA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV732369 | ABM | 1.0 ug DNA | Ask for price |
MCO Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV732645 | ABM | 1.0 ug DNA | Ask for price |
MEB Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
LV732675 | ABM | 1.0 ug DNA | Ask for price |